Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
111M
-
Number of holders
-
75
-
Total 13F shares, excl. options
-
70.4M
-
Shares change
-
+717K
-
Total reported value, excl. options
-
$319M
-
Value change
-
-$11.3M
-
Number of buys
-
50
-
Number of sells
-
-31
-
Price
-
$4.53
Significant Holders of Tango Therapeutics, Inc. - Common Stock, $0.001 par value per share (TNGX) as of Q2 2022
96 filings reported holding TNGX - Tango Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q2 2022.
Tango Therapeutics, Inc. - Common Stock, $0.001 par value per share (TNGX) has 75 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 70.4M shares
of 111M outstanding shares and own 63.45% of the company stock.
Largest 10 shareholders include TRV GP IV, LLC (19.4M shares), FMR LLC (7.63M shares), BOXER CAPITAL, LLC (6.87M shares), Cormorant Asset Management, LP (4.51M shares), Southpoint Capital Advisors LP (4.5M shares), Casdin Capital, LLC (3.5M shares), BlackRock Inc. (3.16M shares), VANGUARD GROUP INC (3.01M shares), EcoR1 Capital, LLC (2.3M shares), and Bain Capital Life Sciences Investors, LLC (1.92M shares).
This table shows the top 75 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.